News Sentiment

BBNX sentiment intelligence

Beta Bionics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 17.03 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+1.6% over one week, +17.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 1.6% Price digesting
Trend fit Trend inactive 17.2% over four weeks
Fair value -1.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 37
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 9
TradingView 7
Investing.com 3
Quiver Quantitative 3
StockStory 3
Moomoo 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 21
Analyst action 2
Balance sheet 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Moomoo Direct company coverage

Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating

Truist Securities has increased its price target for Beta Bionics (NASDAQ: BBLN) to $22 from $18, while reiterating a "Buy" rating on the stock. This adjustment suggests a positive outlook on the company's financial prospects and stock performance.

Tone
Positive 74/100
Event
Analyst action
Published
14 Jul 2026 14:13
Source
Moomoo
Stock Titan Direct company coverage

If You Invested $1,000 in Beta Bionics, Inc. (BBNX)

This article analyzes the historical performance of Beta Bionics, Inc. (BBNX) stock, specifically calculating the return on a hypothetical $1,000 investment over different periods. It highlights that a $1,000 investment one year ago would now be worth $1,346, a 34.6% increase. Th

Tone
Positive 63/100
Event
Market update
Published
14 Jul 2026 14:13
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Beta Bionics, Inc. Stocks

This article lists several ETFs that invest in Beta Bionics, Inc. (BBNX) stocks, providing details such as market value, weight, issuer, expense ratio, and performance. The ETFs offer investors diversified exposure to the medical technology sector and small-cap companies, among o

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:13
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Beta Bionics, Inc. – NASDAQ:BBNX

This article focuses on the "Price to earnings forward" financial metric for Beta Bionics, Inc. (NASDAQ: BBNX) as reported by TradingView. The page displays the company's stock information, along with navigation to various financial and community features on the TradingView platf

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 09:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Beta Bionics, Inc. – NASDAQ:BBNX

This article provides financial data for Beta Bionics, Inc. (NASDAQ: BBNX), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, indicating the period, value, and change for this specific fina

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 11:10
Source
TradingView
Investing.com Direct company coverage

Beta Bionics CFO Stephen Feider sells $170k of BBNX stock

Stephen Feider, CFO of Beta Bionics (NASDAQ:BBNX), sold 10,000 shares of company stock for a total of approximately $170,387 across two transactions in late June. These sales were made under a Rule 10b5-1 trading plan and occurred concurrently with the exercise of employee stock

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:12
Source
Investing.com
The Manila Times Direct company coverage

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

Beta Bionics, Inc. announced its plan to release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. The webcast link and dial

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 10:40
Source
The Manila Times
Stock Titan Direct company coverage

Beta Bionics sets July 29 call for Q2 2026 results

Beta Bionics (Nasdaq: BBNX) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Management will host a conference call and webcast on the same day at 4:30 pm ET to discuss the quarterly performance. The announcement

Tone
Positive 60/100
Event
Earnings
Published
01 Jul 2026 23:40
Source
Stock Titan
PR Newswire Direct company coverage

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations, focusing on whether the company made misleading statements regarding its growth and operating metrics. This investigation comes after Beta Bionics reported Q4 2025 new

Tone
Negative 18/100
Event
Regulatory and legal
Published
01 Jul 2026 15:40
Source
PR Newswire
Stock Titan Direct company coverage

Beta Bionics (BBNX) CFO sells 10,000 shares under 10b5-1 trading plan

Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider sold 10,000 shares of common stock in open-market transactions between June 26 and June 29, 2026, at weighted average prices around $17.04. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan ad

Tone
Negative 41/100
Event
Market update
Published
01 Jul 2026 09:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Beta Bionics For: 29 June By Investing.com

This article announces the filing of Form 144 for Beta Bionics on June 29. It provides stock market data, including various indices, commodities, and individual stock performances, alongside a list of popular news articles from Investing.com. The information is presented as a sna

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 18:41
Source
Investing.com Canada
Stock Titan Direct company coverage

BBNX (NASDAQ: BBNX) notice: proposed sale of 4,896 shares on 06/29/2026

BBNX (NASDAQ: BBNX) has filed a Form 144 notice for the proposed sale of 4,896 shares of Common Stock, identified as stock options, to be sold for cash on June 29, 2026. The filing indicates 44,561,695 shares outstanding as of the same date. Additionally, it records prior sales b

Tone
Neutral 50/100
Event
Balance sheet
Published
29 Jun 2026 17:41
Source
Stock Titan
www.marketscreener.com Direct company coverage

Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 2000 Growth Benchmark

Beta Bionics, Inc. (BBNX) has been removed from the Russell 2000 Growth Benchmark. The medical device company, known for its iLet Bionic Pancreas for diabetes management, also saw its shares drop +1.07% on the day this news was published. This change in index inclusion follows se

Tone
Negative 40/100
Event
Market update
Published
29 Jun 2026 07:36
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 2500 Growth Benchmark

Beta Bionics, Inc. (BBNX) has been removed from the Russell 2500 Growth Benchmark, as announced on June 28, 2026. This follows other recent removals from the Russell 2000 Growth, Russell 3000E Growth, and Russell 3000 Growth benchmarks. The company is a medical device firm focuse

Tone
Negative 19/100
Event
Market update
Published
28 Jun 2026 10:09
Source
marketscreener.com
Stock Titan Direct company coverage

Beta Bionics (BBNX) CCO logs 1,258-share Rule 10b5-1 stock sale

Beta Bionics' Chief Commercial Officer, Mark Hopman, reported an open-market sale of 1,258 shares of common stock on June 24, 2026. The sale, conducted under a pre-arranged Rule 10b5-1 Plan adopted in May 2025, occurred at a weighted average price of $15.0083 per share. Following

Tone
Negative 39/100
Event
Market update
Published
26 Jun 2026 08:10
Source
Stock Titan
Stock Titan Direct company coverage

Director Christy Jones sells BBNX shares under Rule 10b5-1 plan

Beta Bionics director Christy Jones sold 1,406 shares of BBNX Common Stock at $15.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026. Following this transaction, she now directly holds 25,994 shares. The sale, valued at $21,090, was disclosed

Tone
Negative 38/100
Event
Market update
Published
26 Jun 2026 08:10
Source
Stock Titan
TradingView Direct company coverage

BBNX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Beta Bionics, Inc. (BBNX) for 2027, based on analyst opinions. It details the company's financial performance, including past earnings and revenue, future earnings report dates, and key financial metrics like EBITDA. The artic

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:11
Source
TradingView
TradingView Direct company coverage

Beta Bionics, Inc. Actuals & Estimates (BOATS:BBNX)

This article provides an overview of Beta Bionics, Inc.'s (BBNX) financial actuals, estimates, and analyst forecasts. It covers details like stock tickers, price targets, historical highs and lows, upcoming earnings dates, recent earnings per share and revenue figures, net income

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
Investing.com Direct company coverage

Beta Bionics director Christy Jones sells $21,090 in stock

Beta Bionics director Christy Jones sold 1,406 shares of the company’s common stock for $21,090 on June 24, 2026, as part of a pre-planned trading arrangement. This transaction occurred amidst a 52.6% decline in Beta Bionics stock over the past six months, even though the company

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:10
Source
Investing.com
Stock Titan Direct company coverage

10b5-1 sales reported for BBNX insider Christina Jones (NASDAQ: BBNX)

BBNX insider Christina Jones filed a Form 144 reporting planned and recent Rule 10b5-1 sales of restricted stock units. The filing details sales on May 21, 2026, and June 4, 2026, with specific amounts, and relates to Restricted Stock Units dated September 1, 2025. This document

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:09
Source
Stock Titan